# preclinical

Chinese Drugmaker Huadong Advances RNAi Weight‑loss Candidate into Preclinical Studies

Huadong Medicine and Suzhou Shian Biotech have confirmed a preclinical siRNA candidate aimed at an innovative weight‑loss mechanism and entered preclinical research. The move underscores China’s push into RNAi therapeutics for metabolic disease, but substantial scientific, delivery and regulatory challenges lie ahead before any clinical testing.